ERBB2 and gastric cancer: Hence, future studies should highlight the importance of confirmation of HER2 status before giving drugs targeting HER2, as well as exploring the effective biomarkers of pyrotinib and better identifying HER2‐driven GC patients who might benefit more from anti‐HER2‐targeted therapies.